M
Marco Tuccori
Researcher at University of Pisa
Publications - 110
Citations - 3101
Marco Tuccori is an academic researcher from University of Pisa. The author has contributed to research in topics: Medicine & Pharmacovigilance. The author has an hindex of 30, co-authored 95 publications receiving 2359 citations. Previous affiliations of Marco Tuccori include Jewish General Hospital & McGill University.
Papers
More filters
Journal ArticleDOI
Pioglitazone use and risk of bladder cancer: population based cohort study.
Marco Tuccori,Marco Tuccori,Kristian B. Filion,Kristian B. Filion,Hui Yin,Oriana Hoi Yun Yu,Robert W. Platt,Laurent Azoulay,Laurent Azoulay +8 more
TL;DR: The results of this large population based study indicate that pioglitazone is associated with an increased risk of bladder cancer, and the absence of an association with rosig litazone suggests that the increased risk is drug specific and not a class effect.
Journal ArticleDOI
A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Richard E. Kast,John A. Boockvar,Ansgar Brüning,Francesco Cappello,Wen-Wei Chang,Boris Cvek,Q. Ping Dou,Alfonso Dueñas-González,Thomas Efferth,Daniele Focosi,Seyed H. Ghaffari,Georg Karpel-Massler,Kirsi Ketola,Alireza Khoshnevisan,Daniel Keizman,Nicolas Magné,Christine Marosi,Kerrie L. McDonald,Miguel Muñoz,Ameya Paranjpe,Mohammad H. Pourgholami,Iacopo Sardi,Avishay Sella,Kalkunte S. Srivenugopal,Marco Tuccori,Weiguang Wang,Christian Rainer Wirtz,Marc Eric Halatsch +27 more
TL;DR: A treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications is developed to improve prognosis in recurrent glioblastoma.
Journal ArticleDOI
Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Luca Antonioli,Rocchina Colucci,Concettina La Motta,Marco Tuccori,Oriana Awwad,Federico Da Settimo,Corrado Blandizzi,Matteo Fornai +7 more
TL;DR: Current data on the role played byADA in the regulation of immune system activity through its modulation of adenosine pathways is reviewed, with particular attention paid to the involvement of ADA in the pathophysiology of relevant inflammatory diseases.
Journal ArticleDOI
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
Marco Tuccori,S Ferraro,I Convertino,E Cappello,G Valdiserra,Corrado Blandizzi,Fabrizio Maggi,Daniele Focosi +7 more
TL;DR: In this paper, the authors focus on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials.
Journal ArticleDOI
Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
Guido Bocci,Marco Tuccori,Urban Emmenegger,V. Liguori,Alfredo Falcone,Robert S. Kerbel,M. Del Tacca +6 more
TL;DR: Low-dose cyclophosphamide-methotrexate 'metronomic' therapy was assessed to be a cost-effective/cost-saving therapy for palliative treatment for metastatic breast cancer when compared with novel chemotherapy strategies (phase II trials).